Injectable Systems for Long-Lasting Insulin Therapy

Kumar Kulldeep Niloy

University of Tennessee Health Science Center
Injectable Systems for Long-Lasting Insulin Therapy

Abstract
Diabetes mellitus is one of the major global health problems and the prevalence rate is ever increasing reaching to 48% increase by the year of 2040 causing significant economic burdens. Insulin therapy has been the mainstay of diabetes treatment since its discovery in 1922. However, insulin is an unstable peptide with a half-life of only 4-6 min which poses significant challenge in prolonging duration of action of insulin. Nevertheless, the advances in recombinant DNA technology and protein engineering have enabled the development of several long-acting insulin analogue products which show duration of action up to 42 h. However, these insulin analogues still require once- or twice-daily injections for optimal glycemic control resulting in poor compliance and adherence issues among patients. To achieve insulin release for more than one day, different injectable delivery systems including microspheres, in situ forming depots, nanoparticles and composite systems have been developed for sustained release of insulin for days to weeks in in vitro and preclinical studies. Several of these delivery systems have further advanced to clinical trials for once-weekly insulin injection to treat diabetes. Although a number of review articles have appeared in the literature to discuss the developments of long-acting insulin analogues and sustained release insulin delivery systems, none of them comprehensively cover the whole area starting all the way from prototype design and preclinical studies to clinical trials and marketed products. The scope of this review is to fill in the gap and comprehensively summarize the developments of injectable insulin analogues and delivery systems for long-term glycemic control and improved patient compliance.

Document Type
Thesis

Degree Name
Master of Science (MS)

Program
Pharmaceutical Sciences

Research Advisor
Tao L. Lowe, Ph.D.

Keywords
Diabetes, Injectables, Insulin, Sustained Release

Subject Categories
Medicine and Health Sciences | Pharmacy and Pharmaceutical Sciences

This thesis is available at UTHSC Digital Commons: https://dc.uthsc.edu/dissertations/487
Injectable Systems for Long-Lasting Insulin Therapy

A Thesis
Presented for
The Graduate Studies Council
The University of Tennessee
Health Science Center

In Partial Fulfillment
Of the Requirements for the Degree
Master of Science
From The University of Tennessee

By
Kumar Kuldeep Niloy
May 2019
ACKNOWLEDGEMENTS

I would like to express my deepest gratitude to Dr. Tao L. Lowe for her incredible mentorship throughout this journey. I am thankful to Dr. Isaac O. Donkor and Dr. David J. Hamilton to serve in my committee.

I am grateful to our previous and current lab members Dr. Muhammad Gulfam, Dr. Fitsum F. Sahle, Sangyoon Kim, Darren S. Will, Chandana Damera, Faiza Tahia, Emily M. Cooper and Cameron V. Fili for their unconditional support.

I am indebted to my parents, Mr. Nirmal Chandra Kuri and Mrs. Rita Rani Kuri, my wife, Hridita Roy and other family members for their endless patience, care, encouragement, love and support.
ABSTRACT

Diabetes mellitus is one of the major global health problems and the prevalence rate is ever increasing reaching to 48% increase by the year of 2040 causing significant economic burdens. Insulin therapy has been the mainstay of diabetes treatment since its discovery in 1922. However, insulin is an unstable peptide with a half-life of only 4-6 min which poses significant challenge in prolonging duration of action of insulin. Nevertheless, the advances in recombinant DNA technology and protein engineering have enabled the development of several long-acting insulin analogue products which show duration of action up to 42 h. However, these insulin analogues still require once- or twice-daily injections for optimal glycemic control resulting in poor compliance and adherence issues among patients. To achieve insulin release for more than one day, different injectable delivery systems including microspheres, in situ forming depots, nanoparticles and composite systems have been developed for sustained release of insulin for days to weeks in in vitro and preclinical studies. Several of these delivery systems have further advanced to clinical trials for once-weekly insulin injection to treat diabetes. Although a number of review articles have appeared in the literature to discuss the developments of long-acting insulin analogues and sustained release insulin delivery systems, none of them comprehensively cover the whole area starting all the way from prototype design and preclinical studies to clinical trials and marketed products. The scope of this review is to fill in the gap and comprehensively summarize the developments of injectable insulin analogues and delivery systems for long-term glycemic control and improved patient compliance.
TABLE OF CONTENTS

CHAPTER 1. INTRODUCTION .....................................................................................1

CHAPTER 2. INJECTABLE INSULINS IN THE MARKET ......................................4

   Insulin Analogs ................................................................................................................5
   Rapid-Acting Insulin Analogs ..........................................................................................5
      Insulin lispro ........................................................................................................... 5
      Insulin aspart ........................................................................................................... 5
      Insulin glulisine...................................................................................................... 10
   Long-Acting Insulin Analogs ....................................................................................10
      Insulin glargine (100 U/mL) ................................................................................. 10
      Insulin detemir ...................................................................................................... 11
      Insulin glargine (300 U/mL) ................................................................................. 11
      Insulin degludec .................................................................................................... 13
   Premixed Insulins .......................................................................................................13

   Excipients in Long-Acting Insulin Analog Formulations ..............................................15
   Devices for Delivering Insulin Analogs .......................................................................15

CHAPTER 3. INJECTABLE DELIVERY SYSTEMS FOR INSULIN ....................19

   Microspheres ..................................................................................................................19
   In situ Forming Depots ..................................................................................................24
      Thermosensitive In Situ Forming Depots ..................................................................25
      Phase Inversion Based In Situ Forming Depots .........................................................28
      Glucose Responsive In Situ Forming Depots ............................................................32
   Nanoparticles ...............................................................................................................34
   Composite Systems ......................................................................................................41

CHAPTER 4. INJECTABLE INSULINS IN CLINICAL TRIALS ...........................45

   AB101 ............................................................................................................................45
   HM12460A (LAPSInsulin) and HM12470 (LAPSInsulin 115) ..........................................45
   PE0139 (Insumera) ........................................................................................................45
   NN1436 (LAI287) .........................................................................................................47

CHAPTER 5. CONCLUSION AND PERSPECTIVE .................................................48

LIST OF REFERENCES ................................................................................................49

VITA..................................................................................................................................70
LIST OF TABLES

Table 2-1. Currently approved insulin injectables available in the US market.............6
Table 2-2. Excipients in long-acting insulin formulations .............................................16
Table 3-1. Examples of microsphere formulations used in preclinical studies for sustained delivery of insulin.................................................................22
Table 4-1. Injectable sustained release systems for insulin under clinical trials.........46
LIST OF FIGURES

Figure 1-1. Primary structure of native human insulin ..........................................................2
Figure 2-1. Structural modifications of human insulin to develop insulin analogs ..........9
Figure 2-2. Protraction mechanism of insulin analogs ...........................................................12
Figure 2-3. Protraction mechanism of insulin degludec .......................................................14
Figure 2-4. Mechanism of insulin fibrillation in monomeric form ........................................17
Figure 3-1. Summary findings and representative images of sustained release delivery systems for insulin investigated in preclinical studies ..................20
Figure 3-2. Chitosan-zinc-insulin loaded thermo-sensitive non-ionic in situ forming depot ...........................................................................................................27
Figure 3-3. Insulin loaded thermo-sensitive cationic in situ forming depot .......................29
Figure 3-4. Thermo-sensitive pentablock co-polymer based cationic in situ forming depot .............................................................................................................30
Figure 3-5. Phase inversion based in situ forming depot ....................................................31
Figure 3-6. Comparison of blood glucose lowering effect of PLGA phase inversion based in situ forming depot with various zinc sulfate concentration in ZDF rats .................................................................33
Figure 3-7. Sustained release PEG-PLGA nanoparticles ..................................................36
Figure 3-8. Enzyme loaded sustained release nanoparticles ...........................................38
Figure 3-9. Sustained release of insulin from nano-network ...........................................39
Figure 3-10. Glucose responsive enzyme coated nanoparticles ......................................40
Figure 3-11. Microsphere-gel based composite system ..................................................42
Figure 3-12. Nanoparticle-gel based composite system ................................................44
**LIST OF ABBREVIATIONS**

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Full Form</th>
</tr>
</thead>
<tbody>
<tr>
<td>BA</td>
<td>Benzyl alcohol</td>
</tr>
<tr>
<td>BB</td>
<td>Benzyl benzoate</td>
</tr>
<tr>
<td>DOP</td>
<td>Dopamine</td>
</tr>
<tr>
<td>Gp</td>
<td>β-glycerol phosphate</td>
</tr>
<tr>
<td>HA</td>
<td>Hyaluronic acid</td>
</tr>
<tr>
<td>HPMC</td>
<td>Hydroxypropyl methyl cellulose</td>
</tr>
<tr>
<td>HPβCD</td>
<td>Hydroxypropyl-β-cyclodextrin</td>
</tr>
<tr>
<td>p(CPH/SA)</td>
<td>Poly 1,3-bis-(p-carboxyphenoxy) hexane-co-sebacic acid</td>
</tr>
<tr>
<td>p(CPP:SA)</td>
<td>1,3-bis-(p-carboxyphenoxy) propane-co-sebacic acid</td>
</tr>
<tr>
<td>PAE</td>
<td>Poly(β-amino ester)</td>
</tr>
<tr>
<td>PAF</td>
<td>Poly(alanine-co-phenyl alanine)</td>
</tr>
<tr>
<td>PBA</td>
<td>Phenylboronic acid</td>
</tr>
<tr>
<td>PCL</td>
<td>Poly(ε-caprolactone)</td>
</tr>
<tr>
<td>PEG</td>
<td>Poly (ethylene glycol)</td>
</tr>
<tr>
<td>PEO-PPO-PEO</td>
<td>Poly (ethylene oxide)/poly (propylene oxide)/poly (ethylene oxide)</td>
</tr>
<tr>
<td>PHBHHx</td>
<td>Poly(3-hydroxybutyrate-co-3-hydroxyhexanoate)</td>
</tr>
<tr>
<td>PLA</td>
<td>Polylactic acid</td>
</tr>
<tr>
<td>PLGA</td>
<td>Poly(lactic-co-glycolic acid)</td>
</tr>
<tr>
<td>TEM</td>
<td>Transmission electron microscopy</td>
</tr>
</tbody>
</table>
CHAPTER 1. INTRODUCTION

Diabetes mellitus, commonly known as diabetes, is an endocrine disorder characterized by persistently high blood glucose level over a prolonged period. According to CDC National Diabetes Statistics Report published in 2017, nearly 30.3 million Americans, i.e. approximately 1 out of 10 people in US, have diabetes, and among which about 5% of the patients have type 1 diabetes and 95% of the patients are estimated to have type 2 diabetes [1]. The global economic burden of diabetes was estimated $1.3 trillion in 2015 [2]. In US, the total cost of diagnosed diabetes was estimated $327 billion in 2017 including $237 billion for direct medical costs and the rest for reduced productivity of the diabetic patients [2]. Type 1 diabetes is characterized by pancreatic β-cell destruction leading to absolute insulin deficiency; whereas type 2 diabetes is characterized by insulin resistance with a progressive deficiency in insulin secretion by pancreatic β-cells, and [3]. Both type 1 and type 2 diabetes manifest persistent elevation of blood glucose level including blood glucose concentration >125 mg/dL and hemoglobin A1c (HbA1c) level, a form of hemoglobin that is covalently bound to glucose, >6.5% [4]. HbA1c is considered as a well-established surrogate for long-term glycemic control and therefore, reductions in HbA1c reflects long-term glycemic control. However, if untreated, both type of diabetes can cause serious complications including stroke, myocardial infarction, vision loss, amputation, chronic kidney diseases and mortality [5-7]. For patients with type 1 diabetes, multiple daily injections of insulin are the only treatment option. For patients with type 2 diabetes, the treatment starts with management of diabetes through change in life style including healthy eating, weight loss and regular exercise followed by pharmacological intervention with oral metformin monotherapy. If normoglycemia is still not achieved, metformin is given in combination with the following small molecule oral medications: sulfonylurea, thiazolidinedione, DPP-4 inhibitor and SGLT2 inhibitor [8]. However, these oral medications often fail to achieve desired glucose lowering effect, and insulin therapy is eventually included in the treatment regimen when the hemoglobin A1c (HbA1c) level of type 2 diabetic patients is more than 6.5% [9]. Given the prevalence of type 2 diabetes, type 2 diabetic patients account for the use of majority of insulin in the market.

Insulin is an anabolic hormone with a short half-life of 4-6 min and it is secreted from pancreatic beta cells. It regulates the blood glucose level in the body by facilitating the absorption of glucose by different tissues such as liver, fat and muscle tissues. One monomer of regular human insulin consists of an A chain and a B chain linked by two disulfide bridges between two chains and one disulfide bond between two amino acids in A chain. Two monomers form a dimer due to hydrogen bonding and hydrophobic interactions [10, 11] and B chain residues B8, B9, B12, B16, B21 and B23-28 participate in monomer-monomer interaction to form dimer (Figure 1-1) [12, 13]. Three dimers form a hexamer in the presence of zinc where histidine residue at B10 position of each monomer co-ordinates with zinc ion and A13, A14, A17, B1, B2, B4, B13, B14 and B17-19 residues participate in dimer-dimer interaction (Figure 1-1) [12, 13]. Insulin remains as hexamer in glucose regulated secretory vesicles of pancreatic beta cells. High blood
Figure 1-1.  
**Primary structure of native human insulin**
The green indicates residues participating in monomer-monomer interaction leading to dimerization, blue arrow indicates residue participating in dimer-dimer interaction to form hexamer, black arrow indicates residue participating in co-ordination complex with zinc ion and red indicates residues participating in insulin receptor binding.
glucose concentration causes influx of a large amount of glucose inside the beta cells through glucose transporter GLUT-2 which is preferentially expressed in the pancreatic beta cell membrane [14]. This influx causes over production of cytosolic ATP which promotes the closure of ATP sensitive potassium channels on the cell membrane [15]. As a result, K+ ions are accumulated inside the cells causing depolarization of the plasma membrane which in turn causes opening of the voltage-gated Ca2+ channels [15, 16]. As a consequence, cytosolic Ca2+ concentration is raised and triggers exocytosis process by which insulin containing secretory vesicles fuse with the plasma membrane and secrete insulin hexamer [17].

The insulin hexamer is dissociated into monomer when secreted from the pancreas [18, 19]. The insulin monomer is absorbed into the systemic circulation and reaches adipose and muscle tissues where it binds with its receptor to exert its glucose lowering effects on muscle and adipose tissues [20]. The amino acid residues A1, A5, A19, A21, B10, B12, B16 and B23-25 participate in receptor binding of insulin [12]. In a healthy person, insulin is continually secreted from the pancreas at a nearly constant rate and maintain constant plasma insulin level after food absorption is ceased [21]. This is called basal insulin secretion. After each meal, blood glucose level rises due to food absorption and causes a surge in insulin secretion from the pancreas to facilitate glucose utilization by the body which is called post-prandial insulin secretion [21].

Currently there are two types of insulin available in the market based on their duration of action: rapid-acting or bolus insulins including insulin lispro, aspart and glulisine which mimic the post-prandial insulin secretion and long-acting or basal insulins including insulin glargine, detemir, and degludec which mimic the basal insulin secretion from pancreas. Rapid-acting or bolus insulins are used after each meal to control the post-prandial rise in blood glucose level whereas basal or long-acting insulins are used to maintain stable blood glucose level during fasting state or between meals. The rapid-acting insulins require multiple injections in a day and long-acting insulins require once-daily injection for short-term glycemic control i.e. blood glucose concentration < 125 mg/dL and long-term glycemic control i.e. HbA1c < 7%, respectively. Repeated daily injections can cause serious patient non-compliance leading to non-adherence to treatment and consequently, sub-optimal therapeutic outcomes [22].

To address these issues, substantial efforts have been made in the developments of injectable sustained release systems that can release insulin for days to weeks to maintain normoglycemia and eliminate the need of frequent dosing. Along with more conventional sustained release systems including microspheres and in situ forming depots which have been around for a few decades, several new technologies for sustained drug delivery including nanoparticles, composite systems and glucose responsive systems have also been investigated for sustained insulin release. Currently, a number of products have advanced to clinical trials with the potential to transform the current once-daily basal insulin therapy to once-weekly therapy. This thesis comprehensively reviews the current trends and recent advancements in the development of injectable insulin analogs and delivery systems from prototype design and preclinical studies to clinical trials and marketed products as well as provides perspectives on future research and product development in the field of long-lasting injectable insulin therapy.
CHAPTER 2. INJECTABLE INSULINS IN THE MARKET

Since its discovery in 1922, insulin has been mainstay treatment for patients with diabetes mellitus. Insulin was first extracted from the pancreas of cows and pigs in 1921 by Frederick Banting and Charles Best. The extraction process was patented by Banting and Best and later they decided to merge with Eli Lilly when the demand of insulin for the treatment of diabetes surpassed their laboratory production limit [23]. Since then, bovine and porcine insulins were life-saving medicine for diabetes patients, but the short half-life (4-6 min) of insulin required frequent injection which was expensive as well as caused medication non-adherence among patients. Therefore, extensive research efforts were made to increase the duration of action of insulin between 1930-40. The first breakthrough was made possible by Hans Christian Hagedorn at Nordisk Insulin Laboratorium in 1936 [24]. He discovered that the action-time profile of injected insulin could be prolonged by the addition of protamine. Protein molecules usually bear charges because of the ionic nature of the amino acids. Therefore, different protein molecules are soluble in different pH. The solubility of proteins is the least at its isoelectric point [25]. The addition of protamine in insulin increased its isoelectric point from 5.2 to close to physiological pH resulted in the precipitation of insulin upon subcutaneous injection. As a result, insulin was released slowly from the site of insulin precipitation. Further experiments suggested that addition of zinc in insulin-protamine mixture formed insulin crystals which further prolonged the insulin release from the injection site [26]. This discovery led to the commercialization of insulin-protamine-zinc formulation in 1950 by Nordisk which was called NPH (neutral protamine hagedorn) insulin. The NPH insulin maintains its effect for 10-16 h but its absorption rate is unpredictable with high initial burst and rapid fall from the peak concentration [27]. Therefore, NPH insulin is usually mixed with regular insulin to achieve smoother action-time profile and better glycemic control [28]. NPH insulin is the first long-acting insulin formulation introduced in the market.

However, the insulins made from cows and pigs were reported to elicit allergic reactions and immunological responses [29-32]. With the later advent of recombinant DNA technology, biosynthetic human insulin was invented to replace bovine and porcine insulins. Genentech was the first company to develop recombinant human insulin (RHI) in 1978 which was approved by FDA in 1982 but they did not commercialize the product by themselves. In 1983, Eli Lilly and Company marketed the product under the brand name Humulin® after FDA approval and it is considered the first genetically engineered biologic drug [24]. Later on, Eli Lilly also marketed their own recombinant NPH insulin followed by Novo Nordisk’s recombinant human insulin and NPH. Recombinant human insulin is structurally and functionally similar to regular human insulin produced by natural pancreatic β cells and also has a short half-life of 4-6 min [33]. To increase the half-life of the recombinant human insulin, change of the amino acid sequences in native insulin and conjugation with long chain fatty acids to native insulin have been the central strategies to design long-lasting insulin analog. In addition, excipients such as zinc, meta cresol, glycerol and protamine sulfate have also been used extensively in insulin formulation development because zinc promotes insulin hexamer formation [10, 11],
meta cresol stabilizes insulin [34], glycerol is a tonicity adjuster [35], and protamine sulfate can increase the isoelectric point of insulin from 5.2 to close to physiological pH to form insulin precipitates after subcutaneous injection [26]. In this Chapter 2, I focus on the review of two major types of human insulin analogs that have been available in the market: rapid acting or mealtime, and long-acting or basal insulin analogs including their analog designs, excipients in the formulations, and devices for delivering the analogs. Table 2-1 provides an overview of currently available insulins and insulin analogs with their action-time profile. [36]

### Insulin Analogs

#### Rapid-Acting Insulin Analogs

Rapid-acting insulin analogs are a type of recombinant insulin that has rapid onset of action with immediate pharmacodynamic effect. The products available in the market that belong to this category are insulin lispro, aspart and glulisine, whose B chain’s amino acid was modified to reduce zinc mediated hexamer formation which is observed in regular insulin [6]. As a result, these insulin analogs are released into the bloodstream rapidly after subcutaneous injection. In this way, these analogs mimic the prandial insulin secretion of the body, the natural insulin secretion by pancreas after each meal, and thus are prescribed by doctors to maintain the blood glucose level after meal. Compared to regular human insulin and NPH insulin, insulin lispro, aspart and glulisine have faster onset of action, higher peak concentration and shorter duration of action. Below are the detailed discussions of the features and functions of insulin lispro, aspart and glulisine.

##### Insulin lispro

The first-in-class rapid-acting insulin analog was insulin lispro which was marketed in 1996 by Eli Lilly under a trade name of Humalog®. Insulin lispro was developed by interchange between proline and lysine at 28 and 29 position in B chain of regular insulin, respectively (Figure 2-1). The inversion of ProB28LysB29 resulted in destabilization and rapid dissociation of formed hexamers into monomers and dimers causing rapid absorption of insulin into the systemic circulation after subcutaneous injection [37]. In 2017, Sanofi received FDA approval for Admelog® which is the first short-acting “follow-on” product of insulin lispro. Admelog® has an amino acid sequence identical to Humalog® and showed similar pharmacokinetic and pharmacodynamic profile in clinical trials [38].

##### Insulin aspart

The second addition in rapid-acting insulin analogs is insulin aspart which was approved in 2000 and developed by Novo Nordisk under a trade name of Novolog®. In
<table>
<thead>
<tr>
<th>Type</th>
<th>Insulin/Insulin Analogs</th>
<th>Trade Name</th>
<th>Manufacturer (Approval Date)</th>
<th>Time of Action</th>
<th>Dosing Time</th>
<th>Route of Administration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rapid-acting or mealtime insulin analogs</td>
<td>Lispro</td>
<td>Humalog®</td>
<td>Eli Lilly (1996)</td>
<td>15 min</td>
<td>3-5 h</td>
<td>before meal</td>
</tr>
<tr>
<td></td>
<td>Admelog®</td>
<td></td>
<td>Sanofi (2017)</td>
<td>15 min</td>
<td>3-5 h</td>
<td>before meal</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aspart</td>
<td>Novolog®</td>
<td></td>
<td>Novo Nordisk (2000)</td>
<td>15 min</td>
<td>3-5 h</td>
<td>before meal</td>
</tr>
<tr>
<td></td>
<td>Fiasp®</td>
<td></td>
<td>Novo Nordisk (2017)</td>
<td>2.5 min</td>
<td>3-5 h</td>
<td>before meal</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gluisine</td>
<td>Apidra®</td>
<td></td>
<td>Sanofi (2004)</td>
<td>15 min</td>
<td>3-5 h</td>
<td>before meal</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Regular human insulin (RHI)</td>
<td>Humulin® R (U-100)</td>
<td></td>
<td>Eli Lilly (1982)</td>
<td>30-60 min</td>
<td>21 h</td>
<td>before meal</td>
</tr>
<tr>
<td></td>
<td>Novolin® R</td>
<td></td>
<td>Novo Nordisk (1991)</td>
<td>30-60 min</td>
<td>10-16 h</td>
<td>before meal</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Long-acting or basal insulin analogs</td>
<td>Neutral protamine Hagedorn (NPH)</td>
<td>Humulin® R (U-500)</td>
<td>Eli Lilly (1994)</td>
<td>&lt;15 min</td>
<td>~ 24 h</td>
<td>once or twice daily</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Glargine (100 U/ml)</td>
<td>Lantus®</td>
<td></td>
<td>Sanofi (2000)</td>
<td>2-4 h</td>
<td>No peak</td>
<td>~ 24 h</td>
</tr>
<tr>
<td></td>
<td>Basaglar®</td>
<td></td>
<td>Eli Lilly (2015)</td>
<td>2-4 h</td>
<td>No peak</td>
<td>~ 24 h</td>
</tr>
<tr>
<td>Detemir</td>
<td>Levemir®</td>
<td></td>
<td>Novo Nordisk (2005)</td>
<td>3-4 h</td>
<td>No peak</td>
<td>20-24 h</td>
</tr>
<tr>
<td>Glargine (300 U/ml)</td>
<td>Toujeo®</td>
<td></td>
<td>Sanofi (2015)</td>
<td>6 h</td>
<td>No peak</td>
<td>~ 32 h</td>
</tr>
<tr>
<td>Degludec</td>
<td>Tresiba®</td>
<td></td>
<td>Novo Nordisk (2015)</td>
<td>3-4 h</td>
<td>No peak</td>
<td>~ 42 h</td>
</tr>
</tbody>
</table>

Table 2-1. Currently approved insulin injectables available in the US market
Table 2-1. (Continued)

<table>
<thead>
<tr>
<th>Type</th>
<th>Insulin/Insulin Analogs</th>
<th>Trade Name</th>
<th>Manufacturer (Approval Date)</th>
<th>Time of Action</th>
<th>Dosing Time</th>
<th>Route of Administration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Premixed insulins</td>
<td>70% neutral protamine hagedorn and 30% regular human insulin</td>
<td>Humulin® 70/30</td>
<td>Eli Lilly (1989)</td>
<td>30-60 min</td>
<td>12-18 h</td>
<td>SC</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Novolin® 70/30</td>
<td>Novo Nordisk (1991)</td>
<td>30-60 min</td>
<td>12-18 h</td>
<td>SC</td>
</tr>
<tr>
<td></td>
<td>75% insulin lispro protamine and 25% lispro</td>
<td>HumaLog® Mix 75/25</td>
<td>Eli Lilly (1999)</td>
<td>5-15 min</td>
<td>14-24 h</td>
<td>SC</td>
</tr>
<tr>
<td></td>
<td>50% insulin lispro protamine and 50% lispro</td>
<td>HumaLog® Mix 50/50</td>
<td>Eli Lilly (1999)</td>
<td>5-15 min</td>
<td>14-24 h</td>
<td>SC</td>
</tr>
<tr>
<td></td>
<td>70% insulin aspart protamine and 30% aspart</td>
<td>NovoLog® Mix 70/30</td>
<td>Novo Nordisk (2001)</td>
<td>5-15 min</td>
<td>14-24 h</td>
<td>SC</td>
</tr>
<tr>
<td></td>
<td>70% insulin degludec protamine and 30% aspart</td>
<td>Ryzodeg® 70/30</td>
<td>Novo Nordisk (2015)</td>
<td>15 min</td>
<td>&gt;24 h</td>
<td>SC</td>
</tr>
</tbody>
</table>

Notes: SC=Subcutaneous, IV=Intravascular.
Table 2-1. (Continued)

Figure 2-1. Structural modifications of human insulin to develop insulin analogs

A: The amino acid modifications in rapid-acting insulin analogs decrease hexamer formation and increase insulin solubility and absorption from subcutaneous space after injection causing rapid action-time profile.

B: The amino acid modifications and fatty acid conjugation in long-acting insulin analogs lead to formation of multihexamer structures in subcutaneous space after injection and reversible albumin-binding in the circulation, respectively, causing prolonged duration of action.

insulin aspart, proline at B28 position of regular insulin was substituted with aspartic acid (Figure 2-1). As a result, the insulin’s hexamer formation is inhibited, isoelectric point is reduced and solubility at physiological pH is increased due to the negative charge of aspartic acid, and thus insulin is rapidly available in the bloodstream upon subcutaneous injection [39]. The pharmacokinetic-pharmacodynamic profile of insulin aspart is similar to that of insulin lispro [40]. In 2017, Novo Nordisk received FDA approval for its insulin aspart brand-named Fiasp® which has additional nicotinamide (vitamin B3) and arginine as excipients in its formulation, to increase the initial absorption rate of insulin [41]. Fiasp® acts faster than Novolog® with 2.5 vs. 15 min onset of appearance in the bloodstream [6, 42].

**Insulin glulisine**

The most recent rapid-acting insulin analog is insulin glulisine which was approved by FDA in 2004 and introduced to the market in 2006 by Sanofi under a trade name Apidra®. In insulin glulisine, the asparagine at position B3 and lysine at position B29 of regular insulin were replaced by lysine and glutamic acid, respectively to decrease the isoelectric point and thus increase the solubility of the insulin (Figure 2-1) [12]. Insulin glulisine demonstrates slightly faster onset of action than insulin lispro and aspart due to the absence of zinc in its formulation (zinc promotes hexamer formation causing slow availability of functional insulin monomer) [12, 43].

**Long-Acting Insulin Analogs**

Long-acting insulin analogs are a type of recombinant human insulin that can continuously provide exogenous basal insulin to maintain normoglycemia for up to 24 h [22, 44, 45]. The products available in the market that belong to this category are insulin glargine, detemir, and degludec. The design strategies for these long-acting insulin analogs include modification of the amino acid sequence of insulin to facilitate hexamer formation and conjugation of fatty acid to the insulin chain to increase the circulation time of insulin (half-life) in the bloodstream via reversible binding with albumin [6]. Below are the detailed discussions of the features and functions of insulin glargine, detemir, and degludec.

**Insulin glargine (100 U/mL)**

The first long acting insulin analog introduced in the market was Sanofi’s insulin glargine which was approved by FDA in 2000 and marketed under a trade name Lantus®. In insulin glargine 100 U/mL, asparagine at A20 position of regular insulin was replaced with glycine and two arginine molecules were added to the B chain of regular insulin to shift the isoelectric point of insulin close to physiological pH (Figure 2-1) [46]. As a result, insulin glargine 100 U/mL is soluble in acidic pH in the vial but precipitates to form zinc mediated hexamer aggregates leading to slow insulin release after subcutaneous injection. Insulin glargine 100 U/mL demonstrated a flatter and longer pharmacokinetic-pharmacodynamic profile than NPH insulin and can decrease the risk of
nocturnal hypoglycemia in most patients in once daily-dosing [47, 48]. In 2015, FDA approved the first “follow-on” product of insulin glargine developed by Eli Lilly and Company and marketed as Basaglar®. Basaglar® and Lantus® are structurally identical and have similar efficacy and safety profile [49].

**Insulin detemir**

Insulin detemir is the second long-acting insulin analog approved by FDA (2005) and commercialized by Novo Nordisk under a trade name Levemir®. In detemir, threonine was removed from the position B30 and myristoyl fatty acid (C14) was conjugated to B29 lysine of regular insulin to promote di-hexamer formation of insulin with zinc after subcutaneous injection (Figure 2-1). The di-hexamers are dissociated into hexamers and then slowly into monomers to be absorbed in the systemic circulation. In addition, the conjugated fatty acid facilitates reversible binding of insulin with albumin in the systemic circulation to further prolong the action of detemir. In clinical trials, insulin detemir showed better glycemic control than NPH insulin [48, 50]. Although same glycemic control was achieved by insulin detemir in higher dose when compared with insulin glargine 100 U/mL, insulin detemir causes less weight gain than insulin glargine 100 U/mL in clinical trials [51, 52].

Both insulin glargine 100 U/mL and insulin detemir have advantages over NPH insulin because of their longer duration of action, lesser inter- and intra-individual variabilities and fewer episodes of hypoglycemic events [33]. In comparison with insulin glargine 100 U/mL, insulin detemir has even less pronounced inter- and intra-individual variabilities [53]. Although insulin glargine 100 U/mL and detemir are reported to provide glycemic control for 24 h, more frequent than once-daily regimen has been observed to provide improved glycemic control in clinical practice [51, 54]. Considering these issues, newer basal insulin analogs have been developed with a view to providing better glycemic control with fewer injections by improving patient compliance [55]. At present, there are two such basal insulin analogs available in the US market: insulin glargine 300 U/mL and insulin degludec 100 U/mL and 300 U/mL. They are usually prescribed as once-daily injection.

**Insulin glargine (300 U/mL)**

Insulin glargine injection 300 U/mL is a highly concentrated version of Lantus® available in 300 U/mL. It was approved by FDA in 2015 and is currently marketed by Sanofi under a trade name of Toujeo®. After subcutaneous injection, insulin glargine 300 U/mL precipitates at physiological pH to form concentrated insulin-zinc hexamer aggregates which are more compact than aggregates formed by insulin glargine 100U/mL (Figure 2-2). Therefore, insulin glargine 300 U/mL showed longer action than NPH and insulin glargine 100 U/mL [56]. In clinical studies, insulin glargine 300 U/mL demonstrated better steady-state pharmacokinetic-pharmacodynamic profile, better 24 h coverage irrespective of the injection time with less increase in the glucose level in the last 4 h, and reduced risk of nocturnal hypoglycemia than insulin glargine 100 U/mL [57, 58].
Figure 2-2. Protraction mechanism of insulin analogs

The effect of self-aggregation nature of insulin and insulin analogs on their rate of absorption and duration of action has been shown. Preventing hexamer formation by amino acid modification in rapid acting analogs causes rapid dissociation of hexamer into monomer and dimer resulted in fast absorption rate and short duration of action (lispro, aspart and glulisine). Positively charged protamine stabilizes native insulin hexamer and causes slower insulin release and longer duration of action (NPH insulin). Amino acid modification and fatty acid conjugation in long acting insulin analogs cause formation of dihexamer (detemir), hexamer aggregates (glargine) and multi-hexamer chains (degludec) and slows down the absorption and prolongs duration of action. Fatty acid conjugation further extends the half-life by binding with albumin in the circulation (detemir and degludec).

**Insulin degludec**

Insulin degludec was developed by Novo Nordisk as a longer acting version of their previous analog, insulin detemir. Insulin degludec is available in 100 U/ml and 200 U/ml formulations and approved for once-daily dosing regimen. It was approved in 2015 and marketed under the trade name of Tresiba®. In degludec, Threonine at position B30 of regular insulin was removed and a C16 fatty acid was attached to the LysB29 via a Glutamic acid spacer (Figure 2-1) [43]. In the presence of phenol and zinc, insulin degludec forms dihexamer in the vial. Following subcutaneous injection, phenol is diffused out resulting in the formation of multi-hexamer chains. Multihexamers are gradually dissociated into dimers and monomers by the removal of zinc which provides slow and continuous delivery of insulin degludec into the circulation for a prolonged time (Figure 2-3). The protraction is further achieved by reversible binding of degludec with circulating albumin [59, 60] (Figure 2-2). In clinical trials, insulin glargine demonstrated a flat and stable glucose lowering effect [61], four-fold decrease in within-subject variability in glucose lowering effect [61] and reduction in nocturnal hypoglycemia when compared with insulin glargine [62]. Till date, insulin degludec is the longest acting insulin analog available in the market with a duration of action about 42 h with a flexible dosing regimen. As a result, patients who are on once daily insulin degludec dosing regimen, in case of missing dose, can take the dose with time intervals of minimum 8 hours to maximum 40 hours without compromising the glycemic control [63, 64]. On the contrary, insulin glargine and detemir are required to be injected every day (often twice-daily) at the same time to maintain normoglycemia [64].

**Premixed Insulins**

Premixed insulins are developed by combining regular human insulin or rapid acting analogs with its protamine complex to achieve better glycemic control and limit the number of injections per day. Currently, there are six premixed insulins available in the US market (Table 2-1). Regular insulin based premixed formulations (Novolin® 70/30 and Humulin® 70/30) are prepared by mixing 70% NPH insulin and 30% regular human insulin. Premixed formulations prepared from insulin analogs (NovoLog® Mix 70/30, Humalog® Mix 75/25 and Humalog® Mix 50/50) usually contain rapid acting analogs mixed with its protamine complex in variable amount and they usually demonstrate shorter onset and longer duration of action compared to regular premixed preparations. In clinical trial, one injection of premixed insulin decreased HbA1c level significantly (0.2%) compared to one injection of long-acting and one injection of short-acting insulin [65]. Also, premixed insulin analogs have been found to provide better post-prandial glycemic control compared to premixed human insulin, although longer-term glycemic control was comparable for both [66]. Patients usually prefer premixed insulin because of less number of injections, however, they are inconvenient for intensive insulin regimens which may require full basal bolus regimen which is up to 4 injections per day [65]. In this regard, Ryzodeg® 70/30, a premixed insulin with 70% insulin degludec and 30% insulin aspart, showed successful glycemic control with fewer injections than a basal-bolus regimen with significantly less weight gain and lower daily insulin dose (12%) in
Figure 2-3. Protraction mechanism of insulin degludec
Insulin degludec remains as dimer in vial in the presence of zinc and phenol. Upon subcutaneous injection, phenol is diffused out and multi-hexamer chains are formed. Slow removal of zinc causes dissociation of multihexamer chains into monomer and dimer for absorption.
Excipients in Long-Acting Insulin Analog Formulations

In order to promote hexamer formation and albumin binding to achieve longer action-time profile, the amino acid modification and fatty acid conjugation are usually done in B26-30 of insulin residues which preserves its biological activity [68, 69]. Various excipients are also added to the insulin formulations to stabilize the hexamer (Table 2-2). Thus, excipients, along with structure modifications, also play a key role in formulation development of long acting insulin products.

However, insulin undergoes fibrillation when exposed to elevated temperature, agitation, low pH, organic solvents and increased ionic strength [70, 71]. Insulin fibrillation is a limiting factor in long term storage of marketed insulin preparations and predominantly occurs when insulin remains in its monomeric state [72]. Upon long term storage, conformational distortion of the monomers leads to partially folded intermediate and this partial fold may unfold completely or form amyloidogenic nuclei which ultimately leads to the formation of insulin fibril/filament (Figure 2-4) [73]. To overcome this problem, insulin needs to remain in its hexameric form in the marketed preparations and addition of zinc and phenolic compounds such as phenol and meta cresol to the insulin formulations facilitates this hexamer formation by exploiting the self-association nature of insulin monomers [72, 74]. Therefore, all long acting insulin formulations available in the market contain zinc, glycerol and phenol or meta cresol or both. As mentioned earlier, addition of zinc promotes hexamer formation while glycerol is used to adjust the tonicity of the formulation. Phenol and meta cresol are primarily used as preservative as well as hexamer stabilizer in the formulation. However, NPH insulin formulation contains protamine sulfate which, as previously discussed, is used to increase the isoelectric point from 5.2 to close to physiological pH and therefore, insulin is precipitated and forms depot after subcutaneous injection [26]. Addition of phenolic compounds is especially important for degludec and detemir formulations because high concentration of phenolic compounds directs insulin-zinc hexamer to adopt a specific conformation that only allows di-hexamer formation of these analogs in the vial [75, 76]. This process is also driven by anions such as chloride ion and therefore, sodium chloride is also added to detemir and degludec formulation [76]. Besides, Lantus® (insulin glargine) formulation contains polysorbate 20, a surfactant, which is used to prevent turbidity in the formulation [77]. Sodium hydroxide or hydrochloric acid is used to adjust the formulation pH while dibasic sodium phosphate is used as a buffering agent to maintain the pH.

Devices for Delivering Insulin Analogs

Insulin is commonly administered through subcutaneous route due to the ease of self-administration and it is usually delivered using different methods such as vial and syringes, insulin pens, jet injectors and insulin pumps. The most common method of
Table 2-2. Excipients in long-acting insulin formulations

<table>
<thead>
<tr>
<th>Insulin or Insulin Analogs</th>
<th>Trade Name</th>
<th>Excipients (per ml)</th>
<th>Physical Appearance</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neutral protamine Hagedorn (NPH) (5808 Da)</td>
<td>Humulin® N</td>
<td>Human insulin recombinant: 100 U (Escherichia coli), Protamine sulfate: 0.35 mg, Dibasic sodium phosphate: 3.78 mg, Metacresol: 1.6 mg, Phenol: 0.65 mg, Zinc: 0.025 mg (ZnO), Water for injection, Sodium hydroxide and/or hydrochloric acid to adjust pH to 7.7-7.5</td>
<td>White suspension</td>
<td>[78]</td>
</tr>
<tr>
<td></td>
<td>Novolin® N</td>
<td>Human insulin: 100 U (Saccharomyces cerevisiae), Protamine sulfate: 0.35 mg, Zinc: 0.0335 mg, Metacresol: 1.6 mg, Phenol: 0.65 mg, Glycerol: 16 mg, Dibasic sodium phosphate dihydrate: 2.4 mg, Water for injection, Sodium hydroxide (2N) and hydrochloric acid (2N) to adjust pH to 7.1-7.5</td>
<td>White and cloudy suspension</td>
<td>[79]</td>
</tr>
<tr>
<td>Insulin Glargine (100 U/ml) (6063 Da)</td>
<td>Lantus®</td>
<td>Insulin glargine recombinant: 100 U (Escherichia coli), Zinc: 0.03 mg, Metacresol: 2.7 mg, Glycerol (85%): 20 mg, Polysorbate 20: 0.02 mg, Water for injection, Sodium hydroxide and/or hydrochloric acid to adjust pH to ~4 *3 ml prefilled pen does not contain polysorbate 20. All other excipient amounts are same.</td>
<td>Clear aqueous fluid</td>
<td>[80]</td>
</tr>
<tr>
<td></td>
<td>Basaglar®</td>
<td>Insulin glargine recombinant: 100 U (Escherichia coli), Zinc: 0.03 mg, Metacresol: 2.7 mg, Glycerol (85%): 17 mg, Water for injection, Sodium hydroxide and/or hydrochloric acid to adjust pH to ~4</td>
<td>Colorless aqueous solution</td>
<td>[81]</td>
</tr>
<tr>
<td>Detemir (5916.9 Da)</td>
<td>Levemir®</td>
<td>Insulin detemir recombinant (followed by chemical modification): 100 U (Saccharomyces cerevisiae), Zinc: 0.0654 mg, Metacresol: 2.06 mg, Glycerol (85%): 16 mg, Phenol: 1.8 mg, Disodium phosphate dihydrate: 0.89 mg, Sodium chloride: 1.17 mg, Water for injection, Sodium hydroxide and/or hydrochloric acid to adjust pH to ~7.4</td>
<td>Colorless aqueous solution</td>
<td>[82]</td>
</tr>
<tr>
<td>Glargine (300 U/ml) (6063 Da)</td>
<td>Toujeo®</td>
<td>Insulin glargine recombinant: 300 U (Escherichia coli), Zinc: 0.090 mg, Metacresol: 2.7 mg, Glycerol (85%): 20 mg, Water for injection Sodium hydroxide and/or hydrochloric acid to adjust pH to ~4</td>
<td>Clear aqueous fluid</td>
<td>[83]</td>
</tr>
<tr>
<td>Degludec (6103.97 Da)</td>
<td>Tresiba®</td>
<td>Insulin degludec recombinant (followed by chemical modification): 100 U (Saccharomyces cerevisiae), Zinc: 0.0327 mg, Metacresol: 1.72 mg, Glycerol: 19.6 mg, Phenol: 1.50 mg, Di sodium phosphate dihydrate: 0.89 mg, Sodium chloride: 1.17 mg, Water for injection Sodium hydroxide and/or hydrochloric acid to adjust pH to ~7.6</td>
<td>Colorless aqueous solution</td>
<td>[84]</td>
</tr>
</tbody>
</table>
Figure 2-4. Mechanism of insulin fibrillation in monomeric form
Pathway of insulin fibril formation via partial unfolding of monomers leading to amyloidogenic nuclei and insulin fibril/filament.
Insulin delivery is vial and syringes. Although it is the most cost-effective option, there are several disadvantages in this method such as needle phobia of the patients, infection and sickness associated with multiple use of needles, use of incorrect insulin product and inaccurate dose administration [85]. Therefore, this method is becoming less popular among patients and doctors. Insulin pens are gaining preference in this respect owing to their advantage of dose accuracy, reusability and safety features. But they are associated with higher cost in comparison with vials and syringes. In several studies, insulin pens were found to be more accurate than syringes in measuring low insulin dose especially less than 5 units as well as socially more acceptable [85-87]. However, insulin pens are also associated with skin penetration, although to a lesser extent compared to vial and syringe method. Therefore, jet injectors have been developed to deliver insulin without skin penetration. Jet injector uses high pressure narrow jet of liquid insulin formulation instead of needle to penetrate the skin. In diabetic patients, insulin jet injectors showed increased insulin absorption and significant decrease in plasma glucose level compared to insulin pens [88, 89]. Insulin delivered via jet injectors also showed PK profile more close to endogenous insulin and significant improvement in post-prandial glucose control compared to pens in diabetes patients [90]. However, physiologically relevant insulin delivery requires to mimic the pattern of natural insulin secretion from pancreas. Insulin pump therapy can serve this purpose by providing continuous supply of insulin at variable rate in response to the alteration in blood glucose level. In clinical trials, insulin pump therapy showed significant glucose lowering effect, long-term glycemic control and reduction in insulin dose compared to conventional multiple daily injections [91, 92]. Yet, higher cost, inconvenience of constantly wearing it and training requirement limit the broad use of insulin pump among diabetes patients.
CHAPTER 3. INJECTABLE DELIVERY SYSTEMS FOR INSULIN

The concept of using drug delivery systems to prolong the action-time profile of insulin was first materialized by Parkes and Young in 1939 [93]. They implanted solid tablets made of insulin powder in the subcutaneous space in rabbits but unfortunately, it showed slight prolongation of duration of action of insulin compared to regular insulin injection. This unsuccessful attempt led to the use of polyacrylamide slurry for sustained delivery of insulin [94]. Subcutaneous injection of insulin loaded polyacrylamide slurry maintained the growth of diabetic rats at a normal rate until the removal of the implant after 21 days. However, polyacrylamide causes irritation in animal tissues due to its inflammatory nature and therefore, non-inflammatory vinyl acetate-ethylene copolymer was synthesized to develop sustained release implant of insulin [95]. Insulin loaded vinyl acetate-ethylene copolymer disc was implanted subcutaneously in streptozotocin induced diabetic rats. Insulin was released for 29 days in biologically active form and consequently, maintained normoglycemia as well as normal weight gain. Vinyl-acetate-ethylene copolymer was non-inflammatory in nature but the need for surgical implantation and removal of the implant was inconvenient. As a consequence, biodegradable and injectable liposomal system was developed with egg lecithin which resolved the issues related to surgical procedure and inflammation [96]. But the glucose lowering effect was observed only for little more than 7 hours, although a small response still remained 24 h after injection. To extend the release of insulin with biodegradable systems, albumin microbeads were prepared which showed sustained release of insulin for more than two weeks after subcutaneous implantation [97, 98]. Although albumin microbeads demonstrated sustained insulin release and eliminated the need of surgical removal of implant, the surgical implantation still remained an issue which was finally resolved by the use of polylactic acid (PLA) based microcapsules [99, 100]. Insulin loaded PLA microcapsules maintained normoglycemia for five days in diabetic rats. This was the earliest example of a biodegradable injectable system for sustained delivery of insulin. In the next few decades, the use of poly lactic acid and polyglycolic acid (PLGA) based polymers gave rise to the development of numerous sustained release systems. As a consequence, complex dosage forms such as microspheres, nanoparticles, in situ forming depots, and composite systems have emerged as novel delivery technologies for sustained release of insulin (Figure 3-1). This chapter will give a brief overview of each of the systems along with their advantages and limitations.

Microspheres

Microspheres are spherical particles with a size range of 1-1000 μm and are usually prepared from natural or synthetic polymers. In the last few decades, microsphere based delivery systems have been extensively investigated for sustained release of protein and peptide drugs [101, 102]. Microspheres have been shown to release drugs over a long time spanning from days to months [102-104]. Starting in the late 90s, the concept of using biodegradable polymers to develop sustained release microspheres for insulin was pioneered by Lin et al. by emulsification-solvent evaporation method [99, 100]. The
Figure 3-1. Summary findings and representative images of sustained release delivery systems for insulin investigated in preclinical studies

A: SEM image of insulin loaded salicylic acid-poly(anhydride ester) microspheres. The scale bar represents 100 μm.
B: Illustration of insulin loaded in situ forming depot.
C: SEM image of insulin nanoparticles. The scale bar represents 1000 nm.
D: Illustration of insulin loaded microsphere-hydrogel composite system.

Permissions:
study demonstrated that microspheres prepared from 30 kD poly lactic acid could maintain normoglycemia in diabetic SD rats for 5 days [99]. Coating with ethyl vinyl acetate or wax further prolonged insulin release and maintained normoglycemia for 2 weeks [100]. Since then, numerous injectable microspheres prepared from biodegradable polymers have been investigated for controlled release of insulin. Although numerous biodegradable and biocompatible polymers of natural and synthetic origin were used to produce microspheres for proteins and peptides, the use of polymers to develop microsphere formulations for insulin has been mostly limited to poly(lactic-co-glycolic acid) (PLGA) [105, 106] and polylactic acid (PLA) [107, 108]. Table 3-1 provides examples of microsphere formulations used in preclinical studies for sustained delivery of insulin.

An ideal microsphere should have high API encapsulation efficiency and provide conformational stability and sustained release of the encapsulated protein along with optimum particle size and size distribution for easy injectability and low initial burst [101, 109]. The rate and extent of drug release from microspheres largely depend on all of these factors which, in turn, depend on the composition and fabrication techniques of microspheres. Insulin containing microspheres are usually prepared by water/oil/water (w/o/w) double emulsion-solvent evaporation method and also, to a lesser extent, variation of w/o/w method such as solid/oil/water (s/o/w) [110, 111] and solid/oil/oil (s/o/o) [112]. Insulin microspheres are also prepared by spray drying process [113]. Because of its simple process, robust control on process parameters and inexpensive instrumentation, w/o/w double emulsion-solvent evaporation method is most widely used in this regard [109]. In this method, aqueous insulin is first dispersed in a polymer containing organic solvent to form a w/o emulsion which is called primary emulsion. The primary emulsion is then dispersed into large volume of water (which contains emulsifier) to obtain w/o/w emulsion. In the final step, the organic solvent is evaporated in reduced pressure. This method resulted in relatively small size of insulin containing microspheres ranging from 3-5 μm up to less than 100 μm [108, 114, 115].

However, protein denaturation during microsphere preparation is a major concern in traditional w/o/w method because removal of large volume of water during secondary emulsification step often leads to protein denaturation at the water/solvent surface, low loading efficiency and wide size distribution [116, 117]. To resolve this issue, zinc has been used as insulin stabilizing agents during microsphere preparation. Manoharan et al. demonstrated that the addition of zinc during the primary emulsification step (w/o) increased the physical stability of insulin [118]. In this study, addition of zinc not only stabilized insulin in the microspheres, it also increased the encapsulation efficiency and decreased initial burst release. As a result, insulin was released from the microspheres for more than two weeks [119]. Similarly, addition of cationic polyelectrolyte, poly(ethylene glycol)-b-poly(L-histidine) diblock copolymer (PEG-polyHis), was also shown to decrease the aggregation of insulin at the aqueous/organic interface during microencapsulation process and preserved insulin stability during primary emulsification step [120].

The stability of insulin can also be preserved following s/o/w fabrication method.
Table 3-1. Examples of microsphere formulations used in preclinical studies for sustained delivery of insulin

<table>
<thead>
<tr>
<th>Fabrication Techniques</th>
<th>Polymer, Molecular Weight</th>
<th>Size</th>
<th>Animal Model</th>
<th>Key Findings</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>s/o/w emulsion-solvent evaporation</td>
<td>PLGA (50:50), 6600 Da</td>
<td>15–30 μm</td>
<td>STZ-induced diabetic male Wister rats</td>
<td>low initial burst and sustained insulin release for 2 weeks.</td>
<td>[121]</td>
</tr>
<tr>
<td>w/o/w double emulsion-solvent evaporation</td>
<td>p(CPH/SA) (40:60, 50:50), 24000 Da, 16000 Da</td>
<td>~ 40 μm</td>
<td>STZ-induced diabetic male Sprague-Dawley rats</td>
<td>Sustained insulin release for more than 40 days.</td>
<td>[115]</td>
</tr>
<tr>
<td>w/o/w double emulsion and s/o/w emulsion-solvent evaporation</td>
<td>PLGA (50:50) w/o/w: 55 μm s/o/w: 20 μm</td>
<td></td>
<td>Alloxan-induced New Zealand White rabbits</td>
<td>Sustained insulin release for more than 40 days.</td>
<td>[122]</td>
</tr>
<tr>
<td>w/o/w double emulsion-solvent evaporation</td>
<td>p(CPP:SA) (50:50), 21000 Da</td>
<td>41.5 to 49.8 μm</td>
<td>STZ-induced diabetic male Sprague-Dawley rats</td>
<td>Controlled release of insulin for 35 days.</td>
<td>[123]</td>
</tr>
<tr>
<td>w/o/w double emulsion-solvent evaporation</td>
<td>PLGA (85:15), MW 50000-75000 Da</td>
<td>14-15 μm</td>
<td>STZ-induced diabetic male Sprague-Dawley rats</td>
<td>Multi-arm histidine copolymer loaded microspheres maintained normoglycemic effect for 4 weeks.</td>
<td>[114]</td>
</tr>
<tr>
<td>w/o/w double emulsion-solvent evaporation</td>
<td>PLGA (50:50) and PLA, MW 45000 Da</td>
<td>36-37 μm</td>
<td>Alloxan induced diabetic female Wister rats</td>
<td>Glucose lowering effect maintained for 1 week.</td>
<td>[107]</td>
</tr>
<tr>
<td>w/o/w double emulsion-solvent evaporation</td>
<td>PLA, 21400 Da and PEG, 2000 Da</td>
<td>3-5 μm</td>
<td>STZ-induced diabetic female Sprague-Dawley rats</td>
<td>Sustained insulin release for 1 week.</td>
<td>[108]</td>
</tr>
<tr>
<td>w/o/w double emulsion-solvent evaporation</td>
<td>PLGA (50:50), MW 38000-54000 Da</td>
<td>5.9±0.5 μm</td>
<td>STZ-induced diabetic male Wister rats</td>
<td>Sustained insulin release for 21 days.</td>
<td>[124]</td>
</tr>
<tr>
<td>s/o/w emulsion-solvent evaporation</td>
<td>PLGA (50:50), MW 5800 Da</td>
<td>Not Available</td>
<td>Diabetes prone BB/Wor/Tky rats</td>
<td>Normoglycemia maintained after subcutaneous injection in every 10 days.</td>
<td>[125]</td>
</tr>
<tr>
<td>w/o/w double emulsion-solvent evaporation</td>
<td>PCL, 72000 Da</td>
<td>37-52 μm</td>
<td>STZ-induced male Wister rats</td>
<td>Maintained normoglycemia up to 60 days.</td>
<td>[126]</td>
</tr>
<tr>
<td>s/o/w emulsion-solvent evaporation</td>
<td>PLGA (50:50), MW 6000 Da</td>
<td>0.3-0.5 μm</td>
<td>STZ-induce male Wister rats</td>
<td>Normoglycemia maintained from 7th day to 10th day after injection.</td>
<td>[127]</td>
</tr>
<tr>
<td>w/o/w double emulsion-solvent evaporation</td>
<td>PLGA (50:50), MW 12000 Da</td>
<td>Not available</td>
<td>STZ-induced diabetic Kunming mice</td>
<td>Maintained normoglycemia for about 16 days.</td>
<td>[128]</td>
</tr>
</tbody>
</table>
a slight variation of traditional w/o/w method [129]. In this method, solid insulin particles are dispersed in the polymer solution to form s/o emulsion which is then introduced into large volume of aqueous solution that contains emulsifying agent. The addition of solid protein particle reduces the conformational mobility of insulin which is often observed in dissolved proteins and results in higher protein stability as well as higher encapsulation efficiency [109]. For example, Bao et al. fabricated PLGA microspheres by s/o/w process and insulin encapsulation was found to be more than 90% (w/w) with an insulin loading efficiency of 15% (w/w) [111]. The system also showed significantly lower initial burst compared to insulin containing microspheres prepared by w/o/w method.

Spray drying method is another method to prepare insulin loaded microspheres. The main advantages of this method are easy process control and convenience in scale-up [130, 131]. In this method, protein solution or emulsion (w/o or s/o) is atomized at an elevated temperature to evaporate the organic solvent [109, 132]. The insulin containing microspheres prepared by spray drying method demonstrated lower initial burst and maintained its chemical and conformational stability [133]. Different excipients added during spray drying process are also found to modulate microsphere properties. For example, co-encapsulation of HPβCD with insulin in PLGA microspheres slowed down the insulin release rate and maintained conformational stability of encapsulated and released insulin [133]. Similarly, insulin encapsulated with phospholipids such as glycerol monostearate and glycerol distearate in PLGA microsphere showed higher encapsulation efficiency of about 90% [113].

As mentioned, the high initial burst is a major problem in microsphere-based sustained release delivery systems because of uneven distribution of drug molecules and its porous surface which allow easy diffusion of encapsulated drugs [134, 135]. This problem is paramount especially for insulin where higher initial burst can cause severe hypoglycemia resulting in life-threatening situation. To address this problem, double walled PLGA microsphere was developed using water/oil/oil/water (w/o/o/w) emulsion solvent evaporation technique and compared with microspheres prepared by conventional w/o/w method [106]. Double walled microspheres exhibited non-porous smooth surface, smaller particle size and significant reduction in initial burst compared to microspheres prepared in conventional way. The higher initial burst also depends on the nature of the polymer. The hydrophilic characteristics of polymer also affect the initial burst and overall release of insulin from the microspheres. For example, Presmanes et al. demonstrated that acid terminated PLGA microspheres (more hydrophilic) showed higher initial burst compared to ester terminated PLGA microspheres (which is less hydrophilic) [124]. As a result, ester terminated PLGA microspheres maintained hypoglycemic effect up to 4 weeks while acid terminated PLGA microspheres showed hypoglycemic effect for less than two weeks. Molecular weight of the polymers is another important factor affecting the size, encapsulation efficiency and drug release from the microsphere [136, 137]. High molecular weight PLGA microsphere (35813 Da) generated larger particle size compared to low molecular weight PLGA microspheres (6065 Da) but insulin encapsulation efficiency was found to be lower for high molecular weight microspheres [138]. High MW PLGA microsphere also demonstrated lower initial burst of insulin prolonged insulin release compared to low MW microspheres [138].
Several microsphere based sustained release systems have been developed for insulin which successfully demonstrated long-term normoglycemia ranging from days to months in preclinical studies. Table 3-1 summarizes such preclinical studies in which glucose lowering effect was observed for at least one week after injection of insulin loaded microspheres. It shows that that most of the microsphere formulations used in preclinical studies are prepared from poly lactic-co-glycolic acid. The molecular weight of PLGA used in these studies ranged from 5000 Da to 75000 Da. These PLGA microspheres maintained sustained insulin release for up to five weeks where higher molecular weight microspheres showed longer release profile. The biocompatibility, customizable mechanical and degradation properties, tunable drug release kinetics via structural modification and most importantly, approval from FDA for parenteral administration has made PLGA an attractive polymer for developing controlled release parenteral formulations [139].

Therefore, PLGA based microspheres gained much attention and have been subject to considerable research which led to the approval of several PLGA based microsphere products in the last few years [140]. As a consequence, the first PLGA based insulin microsphere formulation (AB101) has been approved for Phase I first in human clinical trial as a once-weekly treatment for diabetes [141]. However, the formulation of AB101 is different than formulations investigated in preclinical studies. Low molecular weight (5 kD) PEG was first conjugated with B chain N-terminus of recombinant human insulin to facilitate the dissolution of insulin in oil or water based solution during emulsification step [142]. PEGylated insulin was then co-dissolved with PLGA in oil phase and finally uniform microspheres are obtained via o/w emulsion technique [142]. AB101 is formulated in single step emulsification method whereas the microspheres reported in preclinical studies (Table 4) were prepared in double emulsion method which is associated with scale-up production difficulties [109]. In AB101, PEGylation of insulin facilitates dissolution in oil phase which resulted in uniform distribution of insulin in the microspheres leading to predicted release kinetics observed in preclinical studies. On the other hand, the preclinical stage microspheres usually used human or bovine serum insulin suspended in water phase during first emulsification step of microsphere preparation which might lead to uneven distribution of insulin in the microspheres causing burst release and unpredictable release kinetics. In this respect, future development should consider use of long acting insulin analogues, PEGylated/lapidated insulin or coencapsulation of cationic polymers to obtain microspheres with less initial burst and more predictable long term release. Further investigations are also warranted to address the inherent issues of microsphere based technology such as poor in vitro-in vivo correlation, and scale-up production cost to take preclinical formulations into clinical stage [143-145].

**In situ Forming Depots**

Injectable in situ forming depots are low viscosity injectable polymeric solution or suspension which, upon injection, forms a semi-solid or solid polymeric matrix at the injection site [146-148]. The solidification of polymer occurs via different mechanisms
such as photo cross-linking [149, 150] or pH change [151, 152], temperature [153] and solvent exchange [148, 154]. The drug entrapped in the polymeric matrix is released in a sustained manner providing desired drug concentration in the systemic circulation for a prolonged time. The polymers used in this case are usually biodegradable in nature which undergo degradation over time and are eventually cleared from the body. *In situ* forming depots were developed as an alternative controlled release system to overcome some of the disadvantages of microspheres such as high fabrication cost, needle clogging, the need of reconstitution, and migration after injection [143-145]. Among different types of *in situ* forming depots, temperature-sensitive and phase-sensitive (solvent-exchange) systems have been primarily reported for sustained release of insulin.

**Thermosensitive *In Situ* Forming Depots**

Thermosensitive *in situ* forming depots refer to polymeric solution which undergoes solution to gel transition in response to the change in temperature. The temperature at which the phase transition occurs is called critical gelation temperature. Certain polymers are characterized by their lower critical gelation temperature (LCGT) and upper critical gelation temperature (UCGT) [146]. At LCGT, the polymeric solutions remain in solution state with lower viscosity but undergo gelation when the temperature goes above LCGT. When the temperature again starts to approach UCGT, the gel structure starts to rupture and is transformed into solution again. Polymers used to develop thermosensitive *in situ* forming depots usually have their LCGT between room and physiological temperature (37°C) and therefore, they are liquid in room temperature and becomes solidified when injected into the body [155].

Various thermosensitive *in situ* forming depots have been designed as controlled release carrier for insulin [101, 156]. The polymers used in this purpose are usually thermosensitive block polymers which are either non-ionic co-polymers, cationic polymers or less commonly polypeptides. Poloxamers, Poly (ethylene oxide)/poly (propylene oxide)/poly (ethylene oxide) (PEO-PPO-PEO), are the first class of thermosensitive block polymers approved by FDA. They are non-ionic in nature and demonstrate sol-gel transition at body temperature at 15% (w/w) concentration and above [146]. Due to their safety profile and good biocompatibility, poloxamer based *in situ* forming gel systems have been explored for sustained insulin delivery [157, 158]. For example, Yang *et al.* developed a sustained release delivery system using Poloxamer 407 (P407) and Poloxamer 188 (P188) [159]. To improve the mechanical properties, hydroxypropyl methyl cellulose (HPMC) was added to the system. Insulin microcrystal loaded Poloxamer/HPMC (P188:P407:HPMC = 9:20:3 %w/v) formulation demonstrated hypoglycemic effect in diabetic SD rats for 3 days.

Attempts have also been made to deliver insulin with commercially available thermosensitive non-ionic polymer such as ReGel® (PLGA-PEG-PLGA) which is on its way towards FDA approval [160]. Kim *et al.* developed an injectable sustained release formulation for insulin using ReGel® [161]. The formulation was composed of 23 wt% copolymer solution with 0.2% zinc and 5.04 mg/ml insulin loaded formulation achieved
sustained insulin release up to 15 days after a single subcutaneous injection in Sprague-Dawley (SD) rats. The same research group also studied the effect of this formulation on Zucker Diabetic Fatty (ZDF) rat model [162]. In this study, the formulation was developed with 6 mg/ml insulin in 23 wt% copolymer solution with 10 wt% zinc carbonate. A single subcutaneous injection of this formulation maintained steady state plasma levels of exogenous insulin for almost 2 weeks in type 2 diabetic ZDF rat model and consequently, maintained normoglycemia during this period. Similarly, Tahami et al. developed triblock copolymer with PLA and PEG by varying the PLA chain length and insulin (at a dose of 90 U/kg body weight) containing PLA-PEG-PLA copolymer solution (40% w/w) demonstrated continuous insulin release over a period of 3 months and maintained blood glucose level of diabetic male Sprague-Dawley (SD) rats below 200 mg/dL [163]. Moreover, copolymer with higher PLA content showed lower insulin release rate and longer duration of action because higher PLA content introduced more hydrophobicity into the system. Although the delivery system released insulin for several months, the conformational stability and secondary structure was partially reduced. To increase the stability of insulin, Oak et al. used chitosan-zinc-insulin complex and loaded into the previously mentioned PLA-PEG-PLA formulation [153]. Positively charged chitosan was used to stabilize zinc-insulin hexamer in order to reduce the initial burst (Figure 3-2). Chitosan-zinc-insulin complex significantly reduced the initial burst release of insulin when compared with the release in the absence of chitosan and zinc [163]. The delivery system composed of 30% (w/w) copolymer solution released insulin in biologically active form and maintained normoglycemic level in diabetic SD rats for 70 days. Moreover, the delivery system did not produce any inflammation during the study period and insulin, both released and extracted from the implant, was conformationally stable.

Apart from PLGA and PLA based non-ionic block co-polymers, poly(ε-caprolactone) (PCL) was also used as a component to synthesize temperature sensitive block co-polymer for controlled delivery of insulin [164]. Huynh et al. developed 5 mg/ml insulin containing PCL-PEG-PCL (25 wt%) formulation which released insulin for 4 days in diabetic SD rats after a single subcutaneous injection. However, the formulation demonstrated high initial burst (>3500 mU/L) compared to free insulin (<1000 mU/L) which was assumed to be caused by slow in vivo sol-gel transition of the formulation after injection. This problem was resolved by adding cationic poly(β-amino ester) which has been described later in this section.

The use of thermosensitive cationic polymers such as chitosan [165], poly(β-amino ester) [166], poly(amoideamine) [167], poly(ethylene imine) [168], and poly(lysine) [169] is another interesting strategy for the delivery of genes and protein molecules because of their ability to bind anionic biomacromolecules. Insulin is negatively charged in physiological pH and therefore, cationic polymers can provide stability in insulin when mixed together. For example, Tahrir et al. used chitosan/β-glycerol phosphate (CS/β-Gp) co-polymer as a cationic delivery system for sustained insulin delivery [170]. The system released 19% - 63% insulin in vitro for more than 6 days depending on the amount of β-Gp in the system and the released insulin maintained its structural stability during this time. A single subcutaneous injection of CS (2% w/v)/β-Gp (8% w/v)
Figure 3-2. Chitosan-zinc-insulin loaded thermo-sensitive non-ionic in situ forming depot

The thermo-responsive gel forms depot after subcutaneous injection. Degradation of polymer as well as dissociation of insulin from chitosan-zinc-insulin complex prolongs the duration of action of insulin.

formulation encapsulated with 0.01 mg/ml insulin into diabetic Balb/c mice demonstrated glucose lowering effect for 5 days which was significantly longer than that of free insulin solution which only lasted for only several hours. Cationic polymers can also be used to synthesize dual-stimuli-responsive system such as both pH- and temperature-sensitive system. For example, thermosensitive oligo(amidoamine/β-amino ester) (OAAAE) was synthesized as a cationic copolymer for controlled insulin release [171]. At low pH such as pH 6.6, the copolymer remained in its solution state in a wide range of temperature (0 – 70°C) but converted into gel in higher pH such as pH 7.4 (Figure 3-3). Subcutaneously injected insulin (5 mg/ml) loaded OAAAE solution (20 wt%) maintained the insulin level for 5 days in diabetic SD rats.

Similarly, Huynh et al. demonstrated that addition of positively charged poly(β-amino ester) (PAE) can also significantly increase the release duration of insulin from thermosensitive triblock copolymer PCL-PEG-PCL [164, 172]. To resolve the issue of higher initial burst of PCL-PEG-PCL system mentioned earlier in this section, they modified the triblock copolymer (PCL-PEG-PCL) by the addition of PAE into a pentablock copolymer PAE-PCL-PEG-PCL-PAE. Addition of positively charged PAE stabilized insulin by forming ionic bond with negatively charged insulin and also conferred pH responsiveness into the system. At pH 3-4, the pentablock copolymer was dissolved in DI water and remained in solution state but formed gel at physiological temperature and pH upon subcutaneous injection (Figure 3-4). The hydrogel significantly reduced the initial burst of insulin and 10 mg/ml insulin loaded copolymer solution (30 wt%) maintained a steady-state blood glucose level for more than 10 days [172]. This is an interesting example of how temperature sensitive systems can be tailored to obtain desired release profile.

Thermoresponsive sustained release systems has also been developed with polypeptides. One such system was reported by Jeong et al. where synthesized poly(ethylene glycol)-block-poly(alanine-co-phenyl alanine) (PEG-PAF) aqueous solution showed solution to gel transition at 37 °C in a few seconds at a concentration as low as 3-7 wt% [173]. Insulin was loaded to 4 wt% PEG-PAF aqueous solution at a dose of 13.8 mg/kg/rat. A single injection of 0.5 ml formulation showed a glucose lowering effect over 18 days in diabetic rats.

**Phase Inversion Based In Situ Forming Depots**

Phase inversion based in situ forming depots are prepared by dissolving biodegradable and biocompatible polymer in a water-miscible and biocompatible organic solvent and the drug is dissolved or suspended in the polymeric solution [147]. Upon injection, the organic solvent is diffused out and the polymer precipitates forming a depot in the subcutaneous space (Figure 3-5). The drug remains in the depot and is released in a sustained manner via diffusion and erosion of the polymeric depot. Dunn et al. first proposed this system in 1990 by incorporating biodegradable polyesters such as PLA and PLGA in water miscible organic solvents such as N-methyl-2-pyrrolidone (NMP) and dimethyl sulfoxide [137, 154]. Since then, different phase inversion based in situ forming
Insulin loaded thermo-sensitive cationic \textit{in situ} forming depot

Figure 3-4. Thermo-sensitive pentablock co-polymer based cationic *in situ* forming depot

A) PAE-PCL-PEG-PCL-PAE (complex gel) demonstrated no initial burst and maintains steady state plasma insulin level for two weeks. B) Mechanism of insulin release from complex gel: (a) the polymer solution at low temperature and pH forms ionic complex with insulin, (b) gel formation at physiological pH and temperature results, (c) slow degradation of polymer releases insulin in sustained manner.

Figure 3-5. Phase inversion based in situ forming depot
Phase-sensitive PLGA based in situ forming depot precipitates and forms solidified PLGA matrix after injection. Drug is released in a sustained manner from the matrix via diffusion and matrix erosion.
systems have been developed and evaluated for their ability to provide controlled release of various proteins and peptides [174, 175]. Insulin has also been used as a drug in phase inversion based \textit{in situ} forming depots for longer release, although there are very few reports available which are mostly based on PLA and PLGA.

Kang \textit{et al.} used PLA as a polymer to develop a phase inversion based system for controlled delivery of insulin [176]. The delivery system was prepared by dissolving PLA (15 or 30\% \textit{w/v}) in benzyl benzoate (BB) and benzyl alcohol (BA) solvent mixture and insulin was mixed at a level of 4\% \textit{(w/v)}. The systems released 15-75\% insulin for more than 2 months \textit{in vitro}. A change in insulin release was observed when hydrophilic (benzyl alcohol) and hydrophobic (benzyl benzoate) solvent ratio and polymer concentration were changed. Histopathological study showed that the system was non-toxic after 12 weeks of implantation. Although the system showed promising sustained release data in \textit{in vitro} study, the system’s performance is inconclusive due to the lack of \textit{in vivo} data. However, Dhawan \textit{et al.} performed a similar study with PLGA containing phase inversion based system by varying the solvent ratio of benzyl benzoate and benzyl alcohol [177]. Several formulations were developed by changing the PLGA, BB and BA concentration and \textit{in vivo} glucose lowering effect was tested on diabetic male LACA mice. The formulation composed of 2 mg/g insulin, 30 wt\% PLGA and 20\% (w/v) BB and 80\% (w/v) BA showed glucose lowering effect for 16 days after a single injection compared to routine once-a-day insulin administration. SDS-PAGE and CD spectroscopy revealed that insulin released from the formulation in \textit{in vitro} study was conformationally stable.

In a similar study, Anand \textit{et al.} developed another PLGA based phase inversion based systems composed of triethyl citrate (TEC) and acetyltriethyl citrate (ATEC) as plasticizer [178]. The formulations were composed 4\% (w/w) insulin glargine and 5\% (w/w) PLGA dissolved in ATEC and TEC mixture with or without zinc sulfate (0.1-0.5\%). The PLGA gel formulations prepared with insulin glargine particles maintained normal blood glucose level for 10 days after a single subcutaneous injection but showed a sudden blood glucose drop in diabetic ZDF rats possibly due to high initial burst. Addition of zinc sulfate slowed down the blood glucose drop in a concentration dependent manner (Figure 3-6). The use of long-acting insulin analogue glargine and addition of zinc combinedly promoted hexamer formation leading to slower insulin release and steady blood glucose drop in this study. As a result, sustained insulin release was achieved for more than one week even with low concentration of polymer solution (5\% w/w) which provided easy injectability.

\textbf{Glucose Responsive \textit{In Situ} Forming Depots}

Apart from thermo-sensitive and phase inversion based \textit{in situ} forming depots, one new kind of gel based system is glucose responsive polymeric gels developed by co-encapsulation of insulin with glucose responsive enzyme such as glucose oxidase. High glucose concentration triggers glucose oxidase mediated conversion of glucose into gluconic acid which causes local pH drop. Consequently, the polymeric matrix is swelled
Figure 3-6. Comparison of blood glucose lowering effect of PLGA phase inversion based in situ forming depot with various zinc sulfate concentrations in ZDF rats
and degraded causing insulin release which is stopped when blood glucose returns to normal level. One example of such system has been found so far which was developed by Fu et al. and utilized a pH sensitive peptide hydrogel called RATEA-16 [179]. RATEA-16 hydrogel undergoes self-assembly in physiological pH but is disassembled in low environmental pH. After injection, insulin and glucose oxidase loaded hydrogel is self-assembled at physiological pH. In hyperglycemic condition, the conversion of glucose into glucuronic acid decreased the local pH resulting in the disassembly of hydrogel resulting in slow insulin release. The system regulated the blood glucose levels of STZ-induced diabetic rats effectively for up to 8 days.

As discussed, thermosensitive systems are mostly composed of block copolymers with hydrophobic and hydrophilic content whereas phase-sensitive systems are developed with polymers which are soluble in organic solvents such as NMP and DMSO etc. Thermo-sensitive systems can be tuned to vary the rate of insulin release by altering hydrophilic/hydrophobic content of the copolymer [156] as well as by varying the properties of the copolymer components [164, 172]. Similarly, phase inversion based in situ forming depots can be developed with tunable release properties by varying the polymer concentration, solvent composition, and by the addition of additives [180, 181]. Regardless of the system, polymer concentration of 15-30% has been found to demonstrate sustained insulin release for at least one week while maintaining the ease of injectability. However, phase inversion based systems suffer from issues inherent to this system such as local irritation at the injection site due to high amount of organic solvent, polymer instability in the solvent system and denaturation of protein drugs in the presence of organic solvents [147]. In this respect, thermo-sensitive systems are usually preferred for the development of in situ forming depots for sustained insulin release especially due to the absence of organic solvent. However, high initial burst, unpredictable release kinetics, poor in vitro-in vivo correlation, variation in implant size, incomplete implant formation, protein instability due to protein-polymer interaction as well as increase in local pH due to polymer degradation remain issues in both systems [146, 147, 181-184]. Like microspheres, high initial burst during the first few hours after injection is also crucial as it might cause severe hypoglycemia [185, 186]. However, addition of zinc, cationic polymers and use of long-acting insulin analogues have been found to improve the burst release [153, 178]. In addition to this, development of robust in vitro release method that can predict the in vivo release profile from the in situ implant can resolve the issues related to poor in vitro-in vivo correlation and accelerate formulation screening. But unpredictable release kinetics still remains an unresolved problem in this respect even after employing several novel imaging techniques to evaluate implant formation and subsequent drug release kinetics [183, 187].

Nanoparticles

Nanoparticles are carriers with a size range of 10-1000 nm [101]. The emergence of nanoparticle-based drug delivery systems has revolutionized the area of protein and peptide drug delivery. Owing to their advantage of transporting drugs across various biological barriers, improved bioavailability and target specific delivery, nanoparticle-
based drug delivery systems has been widely studied for protein and peptide delivery in the past decade [188, 189].

Nanoparticle-based delivery systems have been mainly investigated for efficient oral delivery of insulin because of their smaller size, enhanced pharmacokinetic property and protective nature towards encapsulated insulin [190-192]. But there are few reports on nanoparticles as a sustained release carrier for insulin delivery. One such study investigated sustained release behavior of insulin loaded positively charged dialkylaminoalkyl-amine-poly(vinyl alcohol)-g-poly(lactide-co-glycolide) co-polymer based nanoparticles with a size range of 122.7 nm to 1762.4 nm [193]. The positively charged copolymer formed nanoparticles with negatively charged insulin via ion mediated nanoparticle aggregation. After subcutaneous injection, the aqueous suspension of nanoparticle aggregates formed an in situ depot which released insulin in vitro for about two weeks. The release profile showed triphasic insulin release starting from initial burst, then pore diffusion and finally insulin release from swollen matrix which is typical in particle based sustained release systems [194]. However, no in vivo study of this system was reported.

Nanoparticles prepared from commonly used polymers have been investigated and sustained in vivo insulin release has been achieved for several days. Abdelkader et al. developed PLGA nanoparticles with size ranging from 200-300 nm and these nanoparticles released more than 60% of insulin for more than 6 days in in vitro release study [195]. Subcutaneous injection of optimized nanoparticle formulation demonstrated significant glucose lowering effect in STZ-induced male SD diabetic rats throughout the six days study compared to free human insulin and insulin-zinc suspension. After 6 days, the % basal glucose level was 86.8% for nanoparticle formulations whereas % basal glucose level increased to approximately 106% for both free human insulin and insulin-zinc suspension. In another study, Haggag et al. reported insulin loaded PLGA-PEG block copolymer based nanoparticles via a slight modification of traditional double emulsion-solvent evaporation method (Figure 3-7) [196]. Increase in PEG content was found to increase the encapsulation efficiency of insulin which might be due to the hydrophilicity of PEG that promotes higher insulin attachment on nanoparticle surface. The nanoparticles were negatively charged with a size range of 200-400 nm and the size was increased with the increase in PLGA content. Also, Subcutaneous injection of insulin loaded nanoparticles, at 25 U/kg body weight dose and 10% PEG content, demonstrated sustained hypoglycemic effect for 6 days in STZ-induced diabetic Swiss TO mice.

Nanoparticle based sustained insulin release has been studied with less commonly used biopolymers such as poly(hydroxybutyrate-co-hydroxyhexanoate) (PHBHHx) copolymer [197]. In this study, insulin was first complexed with phospholipid (soybean lecithin) to increase the lipohilicity of insulin which in turn increased the encapsulation efficiency in PHBHHX nanoparticles. The mean particle size of the nanoparticles was 186.2 nm and the nanoparticles showed very slow in vitro insulin release given that only 20% of insulin was released within the first 31 days. However, the nanoparticles, at a dose of 4 IU/kg, maintained hypoglycemic effect in STZ induced diabetic rats for more than 3 days after single subcutaneous injection. The blood glucose level remained less
Figure 3-7. Sustained release PEG-PLGA nanoparticles
PEG-PLGA block copolymer based insulin loaded nanoparticles synthesized via double emulsion-solvent evaporation method. Insulin maintained its conformational stability in nanoparticles demonstrated in insulin sensitivity study in type 2 diabetic mice as well as showed normoglycemia for 6 days.
than 70% of initial level during this time.

Enzymes have been incorporated into the nanoparticle to achieve enzyme mediated degradation of nanoparticles to release insulin in sustained manner (Figure 3-8). Chou et al. developed insulin loaded self-assembled nanoparticles of 40 nm size with carboxymethyl-hexanoyl chitosan and co-encapsulated with lysozyme to achieve enzyme mediated degradation of nanoparticles [198]. 10 μg/ml lysozyme containing insulin loaded chitosan nanoparticles were injected subcutaneously in STZ-induced diabetic male BLTW:CD1 (ICR) mice. The nanoparticles were degraded by lysozyme and as a result, insulin was released slowly from the system. The nanoparticles with lysozyme maintained normoglycemia for 10 days with a stable blood glucose level whereas the nanoparticles without lysozyme showed normoglycemia for less than 5 days.

Glucose-responsive nanoparticle has been emerged as a newer strategy in the last few years for sustained delivery of insulin [28]. As we know that blood glucose concentration is the central stimuli for native insulin secretion from pancreas, glucose responsive nanoparticles can release insulin in response to the glucose concentration i.e. insulin is released from the system when the glucose concentration rises and is stopped when glucose level returns to normal. Gu et al. developed glucose responsive dextran nanoparticles with a size range of 290-340 nm by encapsulating insulin and glucose-responsive enzymes such as glucose oxidase and catalase [199]. The dextran nanoparticles were then coated with either positively charged chitosan or negatively charged alginate which, when mixed together, formed a nano network (Figure 3-9). In hyperglycemic condition, glucose oxidase mediated conversion of glucose into gluconic acid increased the pH of the environment surrounding nanoparticles. As a result, the nano network underwent pH mediated degradation and released insulin slowly. The insulin release was halted when the glucose concentration returned to normal. A single subcutaneous injection of these nanoparticles maintained normoglycemia for up to 10 days in STZ-induced diabetic male C57B6 mice. Conversely, insulin loaded nano network in the absence of glucose-specific enzyme maintained blood glucose level within the normal range for only 2 days.

Xu et al. developed another intelligent glucose-responsive nano system mesoporous silica nanoparticles [200]. Instead of encapsulating glucose specific enzymes with insulin, the porous surface of the nanoparticles was covered with a layer-by-layer coating of enzymes (glucose oxidase and catalase) and polyethyleneimine (PEI) (Figure 3-10). When glucose level is more than 7 mM, the conversion of glucose into gluconic acid increased the surrounding pH. The increase in pH caused protonation of PEI which resulted in repulsion and subsequent loosening of the PEI layers. Hence, insulin was released through the pores of the nanoparticles. In normoglycemic condition, the PEI layer maintained its integrity and prevented insulin release. Upon single subcutaneous injection, the nanoparticles decreased the blood glucose level and maintained normoglycemia for more than 3 days. The design of these nanoparticles allows tunable insulin release by adjusting the amount of PEI in the nanoparticles.

Glucose responsive moiety such phenylboronic acid has been incorporated as a
Figure 3-8. Enzyme loaded sustained release nanoparticles
Figure 3-9.  Sustained release of insulin from nano-network
component of block copolymer to achieve glucose responsive sustained insulin release [201]. For example, poly(d-gluconamidoethyl-methacrylate-block-3-acrylamidophenylboronic-acid) (p(AAPBA-b-GAMA)) amphiphilic block glycopolymer has been synthesized to develop self-assembled nanoparticles [202]. The self-assembly occurred via cross-linking between diol groups of pAAPBA and pGAMA blocks. The nanoparticles released up to 50% of encapsulated insulin for 48 days in *in vitro* release study in conformationally stable form, although *in vivo* sustained release property of these nanoparticles is yet to be explored [203, 204].

Nanoparticle based drug delivery possess several advantages such as targeted delivery, superior penetration ability through biological barriers, prolonged circulation time, enhanced permeation and retention ability and therefore, have been investigated for their potential in different therapeutic areas. But studies regarding the use of nanoparticles for sustained delivery of insulin is sparse and mostly limited to *in vitro* studies. Furthermore, nanoparticle based sustained release systems, in general, demonstrate several issues similar to microspheres such as variation between *in vitro* and *in vivo* drug release profile, migration from the injection site and stability issues during the nanoparticle synthesis process. Moreover, owing to their smaller size compared to microspheres, nanoparticles often show lack of efficient renal clearance after drug release and long-term safety concerns [205]. Although some studies reported sustained insulin release for several days (maximum 10 days) using different nano systems, the breadth of publications in this area is very limited to evaluate the potential of nanoparticles for long-acting insulin therapy.

**Composite Systems**

Particle based sustained release systems such as microspheres and nanoparticles have demonstrated sustained insulin release and maintained normoglycemia for prolonged duration [108, 115, 153, 176, 196, 198, 206]. However, both microsphere- and nanoparticle-based delivery systems possess some inherent disadvantages such as high initial burst, migration from injection site and occasionally, stability issues during encapsulation [134, 137, 205]. Composite systems such as particle-gel or particle-particle hybrid systems have been investigated in several studies to overcome these issues. Zhao *et al.* recently developed one composite system with phenylboronic acid (PBA) modified PLGA microspheres loaded in dopamine modified hyaluronic acid hydrogel (DOP-HA) [207]. At a low glucose level, PBA crosslinked with dopamine to form hyaluronic acid layer around microspheres which acted as a diffusion barrier for insulin encapsulated in microsphere (*Figure 3-11*). At a high glucose level, PBA-DOP crosslinking is disrupted, and the hyaluronic acid layer detached from the microsphere resulting in insulin release through pores. After subcutaneous injection, the insulin loaded microsphere-gel composite system achieved normoglycemia for two weeks in STZ induced diabetic mice. The advantage of this system is that it involves simple mixing and self-assembly of the formulation components which can facilitate scaling up of this system for clinical translation.
Figure 3-11. Microsphere-gel based composite system
A: Microsphere-gel (MP-gel) composite system composed of phenylboronic acid (PBA) modified poly(lactic-co-glycolic acid) (PLGA) microspheres coated with dopamine (DOP) modified hyaluronic acid (HA) layer. At low glucose level, the DOP-HA layer is densely packed on the microsphere surface which prevents insulin release.
B: At high glucose level, the DOP-HA layer is detached from the microsphere surface causing sustained insulin release compared to PBS, MP-gel without insulin, free insulin solution resulted prolonged normoglycemia.
Similar to microsphere embedded hydrogel system, Liu et al. developed a controlled release system for insulin with PLGA nanoparticle embedded within PVA hydrogel via physical cross-linking [208]. Insulin loaded PLGA nanoparticles with a mean size of 615 nm were prepared by traditional double emulsion-solvent evaporation technique and dispersed in 5% w/v PVA solution. The delivery system released insulin in a sustained manner and maintained normal blood glucose level for 24 hours in diabetic mice after one intraperitoneal injection. Although the delivery system maintained normoglycemia similar to long acting insulin analogues, the intraperitoneal route is a significant concern because of its invasive nature compared to traditional subcutaneous route. In a previous study mentioned in section 4.3, Peng et al. demonstrated that insulin-phospholipid complex loaded PHBHHx nanoparticles maintained therapeutic effect of insulin in diabetic rats for more than 3 days [197]. In a follow-up study, the same group loaded these nanoparticles in thermosensitive chitosan/β-glycerophosphate injectable hydrogel to achieve longer action-time profile of insulin [209]. The glucose lowering effect of this composite system lasted for more than 5 days in diabetic SD rats following single subcutaneous injection (Figure 3-12). This is an excellent example of modifying existing sustained release system to achieve longer release profile that can be applied to other particle based sustained release systems as well.

Another novel strategy in this regard is the development of nanoparticle embedded microsphere based systems [210]. These nanoparticle-in-microsphere systems showed longer drug release profile compared to nanoparticle or microsphere alone [211]. Hasan et al. developed insulin loaded PCL nanoparticles encapsulated in PLGA microsphere [212]. PCL nanoparticles (390 ± 17 nm) were prepared by w/o/w double-emulsion solvent evaporation method and then encapsulated in PLGA microspheres by w/o/w method. The size of the composite microspheres was 111 ± 4 μm and it released insulin for about 4 days after single subcutaneous injection into STZ-induced diabetic rats. Although these preclinical in vivo studies demonstrate that particle-particle or particle-gel based composite systems can provide sustained release of insulin, there are actually very few studies to assess the overall feasibility of composite systems in this respect.
Figure 3-12. Nanoparticle-gel based composite system
Representation of nanoparticle loaded hydrogel based composite system. Insulin containing PHBHHx nanoparticle loaded in thermosensitive chitosan/β-glycerophosphate injectable hydrogel retarded insulin release from nanoparticles and maintained normoglycemia for 5 days.
CHAPTER 4. INJECTABLE INSULINS IN CLINICAL TRIALS

Different injectable delivery systems such as microspheres, in situ forming depots, nanoparticles and composite systems have been explored for their potential to achieve ultra-long action of insulin. Although most of them have been limited to preclinical studies, a number of new candidates based on these delivery concepts are advancing towards clinical trials. In fact, four such candidates are currently in early stage clinical development which offer the hope of once-weekly insulin treatment in the near future (Table 4-1). Different delivery methods have been exploited to develop these candidates such as PEGylation, antibody or polypeptide conjugation and delivery via microsphere to achieve longer action-time profile. The following section discusses the design strategies and clinical status of these once-weekly insulin candidates.

AB101

AntraBio’s AB101 combines the concept of PEGylation and microsphere-based delivery system. As mentioned in section 3.1, it was developed by the attachment of 5 kD linear polyethylene glycol (PEG) polymer with ThrB30 side-chain of native human insulin followed by encapsulation of the in PLGA microsphere [213]. Insulin is released from the microsphere in a sustained manner by diffusion and degradation of PLGA. Single dose subcutaneous administration of AB101 demonstrated slow onset, sustained insulin release and corresponding glucose reductions for 1 week in diabetic rats and dogs [214]. AntraBio Inc. recently announced first-in-human clinical trials of AB101 as a once weekly sustained release insulin delivery system [141]. This is the only microsphere-based insulin formulation which is in Phase I clinical trial.

HM12460A (LAPSInsulin) and HM12470 (LAPSInsulin 115)

Hanmi Pharmaceuticals developed novel insulin analogue called LAPSInsulin and LAPSInsulin 115 by conjugating regular insulin or insulin 115 with constant region of a human immunoglobulin Fc fragment (LAPS carrier) through a 3.4 kD PEG linker [215]. Both of the products demonstrated sustained insulin release and prolonged glucose lowering efficacy for more than a week with a reduction in weight gain in preclinical studies with pigs, SD rats and db/db mice where HM12470 demonstrated better efficacy than HM12460 [216, 217]. Both products are undergoing phase I clinical trial.

PE0139 (Insumera)

PhaseBio Pharmaceuticals has developed PE0139 as a once weekly injection for the treatment of diabetes. In PE0139, native insulin molecule has been genetically fused to elastin-like polypeptide (ELP) biopolymer at AspA21 position. PE0139 is expressed in Escherichia Coli as a genetic fusion of ELP1-120 biopolymer and proinsulin. The
Table 4-1. Injectable sustained release systems for insulin under clinical trials

<table>
<thead>
<tr>
<th>Name</th>
<th>Company</th>
<th>Structural Design</th>
<th>Dosing Frequency</th>
<th>Clinical Trial Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>NN1436 (LAI287)</td>
<td>Novo Nordisk</td>
<td>Not disclosed</td>
<td>Once weekly</td>
<td>Phase I</td>
</tr>
<tr>
<td>AB101</td>
<td>AntraBio Inc.</td>
<td>PEGylated insulin encapsulated in PLGA microspheres</td>
<td>Once weekly</td>
<td>Phase I</td>
</tr>
<tr>
<td>HM12460A/HM12470)</td>
<td>Hanmi Pharmaceuticals</td>
<td>Fc–insulin conjugate</td>
<td>Once weekly</td>
<td>Phase I</td>
</tr>
<tr>
<td>(LAPS Insulin/LAPS Insulin</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>115)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PE0139 (Insumera)</td>
<td>PhaseBio</td>
<td>Elastin-like polypeptide fusion</td>
<td>Once weekly</td>
<td>Phase IIa</td>
</tr>
</tbody>
</table>

proinsulin is then converted into insulin during the downstream processing [218, 219]. In phase I clinical study, PE0139 demonstrated prolonged insulin release along with low peak-to-trough ratio that would enable once-weekly dosing regimen [220]. The molecule is now in Phase 2a clinical trial [221].

**NN1436 (LAI287)**

LAI287 also known as insulin-287 is a once weekly insulin analogue developed by Novo Nordisk. LAI287 has been reported as a lipidated insulin analogue but the detailed design of the analogues is undisclosed [213]. The phase I clinical trials have been completed and the company expects to initiate the Phase II clinical trials very soon [222].
CHAPTER 5. CONCLUSION AND PERSPECTIVE

Since its discovery, insulin has been the mainstay of treatment for diabetes mellitus for nearly 100 years. However, achieving normoglycemia for a prolonged time while avoiding the risk of hypoglycemia as well as achieving patient compliance and medication adherence through less frequent injection have always been major challenges with insulin therapy. The longest acting insulin available in the market requires once-daily injection to maintain desired glucose lowering effect which is still inconvenient for patients and therefore, presents significant risk of medication non-adherence. Thus, several strategies have been explored over the past few decades to prolong the action-time profile of insulin to obviate the need of once-daily injection. These strategies have been divided into two categories: altering amino acid sequences and/or chemical conjugation with polymers to develop long acting insulin analogues and developing sustained release delivery systems such as microspheres, in situ forming depots, nanoparticles and composite systems. The sustained release systems have been successfully demonstrated to release insulin for days to weeks in preclinical studies. However, one major drawback of these preclinical studies is that the system’s performance is only measured by measuring glucose lowering effect which is an indicator of short-term glycemic control. These preclinical reports lack HbA1c reduction study which is more relevant for measuring the performance of long-lasting insulin therapy. Also, there are several other limitations such as lack of compendial in vitro release method, insulin instability, loss of biological activity, poor in vitro-in vivo correlation, higher initial burst, migration of the particle based systems from the injection site, manufacturing costs, need for reconstitution and sometimes unpredictable in vivo release from the delivery systems, which need to be addressed for successful translation of these preclinical strategies into clinical setting. However, advancements in recombinant DNA technology and protein chemistry coupled with the advances in material and formulation sciences as well as microfabrication techniques have been able to address some of these issues and enabled several once-weekly candidates to progress to the clinical trials. Future development efforts should focus on novel macromolecular modifications of insulin such as peptide and antibody conjugation as well as microspheres and in situ forming depots considering significant attention of FDA on the development of these complex sustained release delivery systems. In addition, glucose responsive systems should also be considered as focal point of research and developmental efforts as next generation injectable sustained release system for insulin.
LIST OF REFERENCES


35. Gualandi-Signorini, A., & Giorgi, G. Insulin formulations-a review.


58. Becker, R. H., Dahmen, R., Bergmann, K., Lehmann, A., Jax, T., & Heise, T. (2015). New insulin glargine 300 Units . mL-1 provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 Units . mL-1. *Diabetes Care, 38*(4), 637-43. doi:10.2337/dc14-0006


67. Allé, N. Ryzodeg® provides successful glycaemic control with fewer injections than a basal-bolus regimen.


degludec, an ultra-long-acting basal insulin. *Pharmaceutical research, 29*(8), 2104-2114. doi:10.1007/s11095-012-0739-z


palmitoyl chitosan: In vitro characteristics and in vivo biocompatibility. *Biomaterials, 30*(28), 4877-4888. doi:https://doi.org/10.1016/j.biomaterials.2009.05.052


VITA

Kumar Kulldeep Niloy was born in Rangpur, Bangladesh in 1992. He graduated with Bachelor of Pharmacy degree in 2014 and Master of Pharmacy degree with a focus on Clinical Pharmacy and Pharmacology in 2016 from University of Dhaka in Bangladesh. In August 2017, Niloy joined in The University of Tennessee Health Science Center as a graduate student in Department of Pharmaceutical Sciences. He anticipates completion of the requirements for his Master of Science degree in Pharmaceutical Sciences with a focus on Pharmaceutics in May 2019.